0000830656-12-000013.txt : 20120221 0000830656-12-000013.hdr.sgml : 20120220 20120217173136 ACCESSION NUMBER: 0000830656-12-000013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120217 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20120221 DATE AS OF CHANGE: 20120217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRESSURE BIOSCIENCES INC CENTRAL INDEX KEY: 0000830656 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 042652826 STATE OF INCORPORATION: MA FISCAL YEAR END: 1110 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21615 FILM NUMBER: 12623963 BUSINESS ADDRESS: STREET 1: 14 NORFOLK AVENUE CITY: SOUTH EASTON STATE: MA ZIP: 02375 BUSINESS PHONE: 5082301828 MAIL ADDRESS: STREET 1: 14 NORFOLK AVENUE CITY: SOUTH EASTON STATE: MA ZIP: 02375 FORMER COMPANY: FORMER CONFORMED NAME: BOSTON BIOMEDICA INC DATE OF NAME CHANGE: 19960812 8-K 1 form8k.htm NASDAQ BID PRICE DEFICIENCY form8k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  February 15, 2012

Pressure BioSciences, Inc.
(Exact Name of Registrant as Specified in Charter)
Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS


(State or Other Jurisdiction of Incorporation)
0-21615
  
04-2652826
(Commission File Number)
  
(IRS Employer Identification No.)
 
14 Norfolk Avenue, South Easton, MA
  
 
02375
(Address of Principal Executive Offices)
  
(Zip Code)
(508) 230-1828

(Registrant’s Telephone Number, Including Area Code)

 (Former Name or Former Address, if Changed Since Last Report)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 

 
 

 
 
 


 
 

 

Item 3.01.  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

By letter dated February 15, 2012, Pressure BioSciences, Inc. (the “Company”) was notified by the Listing Qualifications Staff of The NASDAQ Stock Market LLC that, due to the fact that the Company did not achieve compliance with the $1.00 bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2) (the “Bid Price Requirement”) by February 13, 2012, the Company’s non-compliance with the Bid Price Requirement may serve as an additional basis for the delisting of the Company’s common stock from NASDAQ.  As disclosed on August 19, 2011, pursuant to the NASDAQ Listing Rules, the Company was previously granted an automatic 180-day period within which to satisfy the Bid Price Requirement, which expired on February 13, 2012.

On November 17, 2011, the Company attended a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”), at which it presented its plan to regain and sustain compliance with the $2.5 million stockholders’ equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(b)(2).  Following the hearing, and as disclosed on December 8, 2011, the Panel granted the Company’s request for an extension of time to regain compliance with the Stockholders’ Equity Requirement through February 29, 2012.  In anticipation of the notice of non-compliance with the Bid Price Requirement, the Company has already submitted a revised plan of compliance for the Panel’s review and has requested a further extension of time.  While the Company is diligently working to regain compliance with all applicable NASDAQ listing criteria, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to successfully complete its compliance plan.
 

 


 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
PRESSURE BIOSCIENCES, INC.
  
       
Date:  February 17, 2012
  
/ s/ Richard T. Schumacher
  
   
Richard T. Schumacher
  
   
President and Chief Executive Officer